UBS raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $458 from $441 and keeps a Buy rating on the shares. Madrigal’s Q1 is supportive of a major 2025 for metabolic dysfunction-associated steatohepatitis, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals price target raised to $460 from $422 at B. Riley
- Madrigal Pharmaceuticals price target raised to $420 from $394 at Canaccord
- Madrigal Pharmaceuticals Reports Strong Q1 2025 Results
- Madrigal’s Earnings Call: Rezdiffra’s Success and Future Plans
- Madrigal Pharmaceuticals: Strong Financial Performance and Strategic Positioning Justify Buy Rating